As countries around the world roll-out Johnson & Johnson (NYSE:JNJ)’s single-dose COVID-19 vaccine, the company is expected to report second-quarter earnings on Wednesday, July 21st. Investor focus will be on production updates related to the shot, the company’s thoughts on the need for booster doses, and the performance of J&J’s medical device and pharmaceuticals units. Separately, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will meet on Thursday to discuss cases of Guillain-Barré syndrome detected in recipients of the Johnson & Johnson COVID-19 vaccine.
Johnson & Johnson (NYSE:JNJ) is anticipated to report earnings of 9.44% per share for next year, according to research brokerages covering the stock. Analysts are expecting an EPS change of -4.20% for the current year. Wall Street analysts polled by Thomson Reuters have a current recommendation of 1.90 on a consensus basis for the stock. The same analysts see shares reaching $187.39 within the next year on a consensus basis. Let’s take a look at how the stock has been performing recently. Over the past twelve months, Johnson & Johnson (NYSE:JNJ)’s stock was 6.81%. Over the last week of the month, it was -0.97%, 3.61% over the last quarter, and 4.64% for the past six months.
Over the past 50 days, Johnson & Johnson stock’s -3.45% off of the high and 3.08% removed from the low. Their 52-Week High and Low are noted here. -3.96% (High), 24.79%, (Low).
Fundamental analysis examines the financial elements of a company, for example; sales, cash flow, profit and balance sheet. These numbers are then crunched to create theoretical valuations of companies.
Earnings Per Share (EPS) is the earnings made by a company divided by their number of shares. EPS enables the earnings of a company to easily be compared to their competitors. The higher the number, the more profit per dollar is being made on investor capital. Johnson & Johnson’s EPS for the trailing 12 months is 5.66. Their EPS should be compared to other companies in the Healthcare sector.
Price-to-Earnings Ratio is the current share price divided by annual earnings per share. P/E provides a number that details how many years of earnings it will take a stock to recoup the value of one share at current price levels. Easy to calculate and understand, P/E is an extremely common ratio that is used to compare valuations of stocks against each other relatively. Johnson & Johnson’s P/E ratio is 29.69.
Technical analysts have little regard for the value of a company. They use historic price data to observe stock price patterns to predict the direction of that price going forward. Analysts use common formulas and ratios to accomplish this.
Johnson & Johnson (NYSE:JNJ)’s RSI (Relative Strength Index) is 48.53. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions.